Anticoagulant
Study: 20% of patients with kidney disease, no Medicare used antiplatelets on dialysis
Researchers found one-fifth of patients with kidney disease who do not have Medicare have used an antiplatelet and/or anticoagulant during hemodialysis, according to data published in Kidney Medicine.
Insufficient evidence of harm in patients with stroke after recent oral anticoagulant use
There was insufficient evidence of excess harm associated with off-label IV thrombolysis in patients after ischemic stroke with recent intake of a direct oral anticoagulant, researchers reported in JAMA Neurology.
Catheter-directed fibrinolysis safe in intermediate-high-risk pulmonary embolism
In adults with intermediate-high-risk pulmonary embolism, catheter-directed fibrinolysis plus anticoagulation appears safe and was associated with favorable imaging-based findings compared with anticoagulation monotherapy, data show.
In hospitalized patients with AF, discharge on anticoagulation varies by race
Among patients hospitalized with atrial fibrillation, Black patients were less likely to be discharged while taking anticoagulant therapy, and direct oral anticoagulants in particular, than white patients, researchers reported.
VIDEO: Speaker discusses ‘nuanced’ guidance on VTE management
NASHVILLE, Tenn. — In this Healio exclusive, Samantha Pettigrew, MD, discusses CHEST’s 2021 update to its clinical guidelines on using anticoagulation for venous thromboembolism at the CHEST Annual Meeting.
Most women who take anticoagulants for blood clots experience abnormal menstrual bleeding
Two-thirds of women of child-bearing age who began taking anticoagulants for acute venous thromboembolism had abnormally heavy menstrual bleeding in the months that followed therapy initiation, according to data from a prospective study.
Novel anticoagulant therapy receives fast track designation from FDA
Merck announced its investigational factor XI inhibitor to reduce risk for major thrombotic CV events in patients with end-stage renal disease has received fast track designation from the FDA.
Q&A: ‘Primary prevention’ the biggest challenge in managing antiphospholipid syndrome
Reducing the risk for thrombotic events in patients with antiphospholipid syndrome means striking the proper balance of monitoring and anticoagulation therapy, according to Richard A. Furie, MD, of Northwell Health in New York.
Kids-DOTT
Shorter vs. standard anticoagulation duration for children with provoked venous thromboembolism.
Diabetes complications less likely in non-vitamin K antagonist oral anticoagulant users
Adults with atrial fibrillation and diabetes who received non-vitamin K antagonist oral anticoagulants had a lower risk for diabetes complications and mortality than those who received warfarin, a retrospective cohort study showed.